Pharmacological treatment of negative symptoms of schizophrenia: Therapeutic opportunity or Cul-de-sac?

Acta Psychiatrica Scandinavica

Volumn 115, Issue 2, 2007, Pages 93-100

  Buckley, P F ^a   Stahl, S M ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic medications; Measurement; Negative symptoms

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

BEHAVIOR THERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33846297688     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2007.00992.x     Document Type: Review

References (64)

1. ERHART SM, MARDER SR, CARPENTER WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 2006;32:234-237.
2. LECRUBRIER Y, QUINTIN P, BOUHASSIRA M et al. Treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in 6 months double blind controlled clinical trial. Acta Psychiatr Scand 2006;114:319-327.
3. STAHL SM, BUCKLEY PF. Negative symptoms of schizophrenia: A problem that will not go away. Acta Psychiatr Scand 2007;115:4-11.
4. ALPHS L. An industry perspective on the NIMH Consensus Statement on Negative Symptoms. Schizophr Bull 2006;32:225-230.
5. KIRKPATRICK B, FENTON WS, CARPENTER WT JR, MARDER SR. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophr Bull 2006;32:214-219.
6. LAUGHREN T, LEVIN R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 2006;32:220-222.
7. TARRIER N. Negative symptoms in schizophrenia: comments from a clinical psychology perspective. Schizophr Bull 2006;32:231-233.
8. MARDER SR, MEIBACH RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
9. ROSENHECK R, DUNN L, PESZKE M et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999;156:88-93.
10. TOLLEFSON GD, SANGER TM. Negative symptoms: a path analytical approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474.
11. LEUCHT S, PTISCHEL-WALZ G, ABRAHAM D et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
12. MOLLER HJ, MULLER H, BORISON RL et al. A path-analytical approach to differentiate between direct and indirect effects on negative symptoms in schizophrenic patients: a reevaluation of the North-American risperidone study. Eur Arch Psy Clin N 1995;245:45-49.
13. KANE J, HONIGFELD G, SINGER J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatr 1988;45:789-796.
14. BUCKLEY PF, LYS C. Psychotherapy and schizophrenia. J Psychother Pract Res 1996;5:185-201.
15. MELTZER HY, BASTANI B, KWON KY et al. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 1989;99:S68-S72.
16. BREIER A, BUCHANAN RW, IRISH D et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Psychiatr Serv 2000;51:1249-1253.
17. RANJAN R, MELTZER HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996;40:253-258.
18. HAGGER C, BUCKLEY P, KENNY JT et al. Improvement inn cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712.
19. MILLER DD, PERRY PJ, CADORET RJ et al. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994;35:8-15.
20. BREIER A, BUCHANAN RW, KIRKPATRICK B et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26.
21. BUCHANAN RW, BREIER A, KIRKPATRICK B et al. Positive and negative symptom response to clozapine I schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-760.
22. WADDINGTON JL, CASEY D. Comparative pharmacology of classical and (novel) second-generation antipsychotics. In: BUCKLEY PF, WADDINGTON JL, eds. Schizophrenia and mood disorders: the new drug therapies in clinical practice. London: Arnold Publications, 2001, pp. 3-13.
23. MELTZER HY. Clozapine; is another view valid? Am J Psychiatry 1995;152:821-825.
24. CARPENTER WT Jr, CONLEY RR, BUCHANAN RW et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152:827-832.
25. MCEVOY JP, LIEBERMAN JA, STROUP TS, et al. for the CATIE investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
26. ARTALOYTIA JF, ARANGO C, LAHTI A et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in health volunteers. Am J Psychiatry 2006;163:488-493.
27. KOPELWICZ A, ZARATE R, TRIPODIS K et al. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157:987-993.
28. KINON B, VOLVKA J, STAUFFER V et al. Standard and higher doses of olanzapine in acutely ill patients with schizophrenia of schizoaffective disorder with suboptimal prior response: a randomized double blind fixed dose study. Int J Neuropsychopharmacol 2006;9:5281.
29. MARDER SR, DAVIS JM, CHOUINARD G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546.
30. SCHOOLER N, RABINOWITZ J, DAVIDSON M et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-953.
31. LIEBERMAN JA, TOLLEFSON G, TOHEN M, et al. HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404.
32. TOLLEFSON GD, BEASLEY CM, TRAN PB et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders. Am J Psychiatry 1997;154:457-465.
33. ROSENHECK R, PERLICK D, BINGHAM S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2004;290:2693-2702.
34. MULLEN J, JIBSON MD, SWEITZER D. A comparison of the relative safety, efficacy and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the QUEST study. Clin Ther 2001;23:1839-1854.
35. KECK P, BUFFENSTEIN A, FERGUSON J, et al. Ziprasidone Study Group. Ziprasidone 40 mg and 20 mg/day in the acute exacerbation of schizophrenia, and schizoaffective disorder: a 4 week placebo controlled trial. Psychopharmacology 1998;140:173-184.
36. KANE JM, CARSON WH, SAHA AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 1988;63:763-771.
37. LOEBEL A, SIU C, ROMAN S. Improvements in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004;9:357-364.
38. PAILIERE-MARTINOT ML, LECRUBIER Y, MARTINO JL et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995;152:130-133.
39. DANION JM, REIN W, FLEUROT O et al. Improvement of schizophrenic patients with negative symptoms treated amisulpride. Am J Psychiatry 1999;156:610-616.
40. LEUCHT S, PATSCHEL-WALZ G, ENGEL RR et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190.
41. TRAN PV, HAMILTON SH, KUNTZ AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
42. CONLEY RR, MAHMOUD R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;155:914-920.
43. SIMPSON GM, CLICK ID, WEIDEN PJ et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837- 1847.
44. BREIER A, KANE JM, BERG PH et al. Olanzapine versus ziprasidonze: results of the 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-1887.
45. ADDINGTON DE, PANTELIS C, DINEEN M et al. Efficacy and tolerability of ziprasidone in patients wit acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-1633.
46. POTKIN SG, SAH AR, KUJAWA MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690.
47. LIEBERMAN JA, STROUP TS, MCEVOY JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
48. STROUP TS, LIEBERMAN JA, AMCEVOY JP et al. for the CATIE investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622.
49. ARATO M, O'CONNOR R, MELTZER HY et al. A 1-year placebo-controlled double-blind trial of ziprasidone 40, 80, and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-215.
50. BUCKLEY PF. Maintenance treatment of schizophrenia with quetiapine. Human Psychopharmacol 2004;19:121-124.
51. STAHL SM, GRADY MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313-327.
52. STAHL SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 2002;106:321-322.
53. STAHL SM. Antipsychotic polypharmacy - evidence based prescribing or prescribing based evidence? Int J Neuropsychopharmacol 2004a;7:113-116.
54. STAHL SM, FREUDENREICH O, GOFF DC. A successful antipsychotic combination trial. Quo vadis? Acta Psychiatr Scand 2004;10:241-249.
55. GOFF DC, FREUDENREICH O. Focus on polypharmacy in schizophrenia: does anyone truly benefit? Int J Neuropsychopharmacol 2004;7:109-111.
56. BUCKLEY PF, SHENDARKAR N. Treatment-refractory schizophrenia. Curr Opin Psychiatry 2005;18:165-173.
57. SHILOH R, ZEMISHIANY Z, ALZENBERG D et al. Sulpride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo controlled study. Br J Psychiatry 1997;171:569-573.
58. MOLLER HJ. Management of negative symptom of schizophrenia: new treatment options. CNS Drugs 2003;17:793-823.
59. DICKERSON FB, LEHMAN AF. Evidence-based psychotherapy for schizophrenia. J Nerv Ment Dis 2006;194:3-9.
60. TURKINGTON D, KINGDOM D, WEIDEN PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry 2006;163:365-373.
61. HOGARTY GE, KORNBLITH SJ, GREENWALD D et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family. I: description of study and effects on relapse rates. Am J Psychiatry 1997;154:1504-1513.
62. GLYNN SM, MARDER SR, LIBERMAN RP et al. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry 2002;159:829-837.
63. GRANHOLM E, MCQUAID JR, MCCLURE FS et al. A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. Am J Psychiatry 2005;162:520-529.
64. MARDER SR. Integrating pharmacological and psychosocial treatments for schizophrenia. Acta Psychiatr Scand Suppl 2000;407:87-90.